What are the changes?

Pneumococcal vaccines - category A and B at risk conditions simplified into a single list and changes to recommendations for at risk children and adults, Aboriginal adults and non-Aboriginal adult.

Meningococcal B - funded for all Aboriginal children and people with asplenia, hyposplenia, complement deficiency and treatment with Eculizumab.

Meningococcal ACWY vaccine - funded for people with asplenia, hyposplenia, complement deficiency and treatment with Eculizumab.

Haemophilus influenzae type b - funded for people ≥5 years with asplenia and hyposplenia.

Pneumococcal (Prevenar 13 and Pneumovax 23)

General

The list of at risk conditions has been condensed into 1 list i.e. there is no longer a category A and a category B list. All conditions on the consolidated list (available from the online Australian Immunisation Handbook) are recommended to receive pneumococcal vaccination but it is only funded for some - a list of these conditions is available from the Australian Department of Health

The number of doses of Pneumovax 23 is now limited to two lifetime doses.

At risk groups

Children diagnosed with an at risk condition at ≤12 months of age are recommended to receive additional doses as follows:

  • 6 Months - additional dose of Prevenar 13 (or at diagnosis if diagnosed 6-11 months)
  • 4 years - a dose of Pneumovax 23
  • At least 5 years later - a dose of Pneumovax 23

Children and adults diagnosed with an at risk condition ˃12 months of age are recommended​ to receive:

  • At diagnosis - Prevenar 13
  • 2-12 months later or ≥4 years (whichever is later) - Pneumovax 23
  • At least 5 years later - another dose of Pneumovax 23

Aboriginal people aged ≥50 years without an at risk condition are recommended and funded to receive:

  • ≥50 years of age - a dose of Prevenar 13
  • 2-12 months later - a dose of Pneumovax 23
  • At least 5 years later - another dose of Pneumovax 23

Non-Aboriginal adults aged ≥70 years without an at risk condition are recommended and funded to receive a single one-off dose of Prevenar 13 (the single dose of 23vPPV at 65 years is no longer recommended or funded).

Notes

  • Those already 70 years of age or older on 1 July 2020 are eligible for a single one-off funded dose of Prevenar 13 which can be given opportunistically at a suitable clinical encounter.
  • There are no changes to the routine childhood schedule. Infants should still receive Prevenar 13 at 6 weeks, 4 months and 12 months.

Meningococcal B (Bexsero)

Aboriginal children

  • All Aboriginal children ˂2 years of age are recommended and funded to receive three doses of Bexsero at 6 weeks, 4 months and 12 months of age.
  • An additional dose for Aboriginal children <2 years of age with certain at risk conditions may be required. These conditions include asplenia and hyposplenia, complement deficiency, treatment with Eculizumab, HIV and Haematopoietic stem cell transplant – the number of required doses is age based. Refer to the online Australian Immunisation Handbook

Note: Catch up is available for Aboriginal children less than 2 years of age until 30 June 2023 – the number of doses required is based on age. Refer to the online Australian Immunisation Handbook

At risk groups

People with specified risk conditions including asplenia and hyposplenia, complement deficiency, treatment with eculizumab are recommended and funded to receive Bexsero. The number of doses required is based on age. Refer to the online Australian Immunisation Handbook

Meningococcal ACWY (Nimenrix)

  • People with specified risk conditions including asplenia and hyposplenia, complement deficiency and treatment with eculizumab are recommended and funded to receive Nimenrix. The number of doses required are based on age. Refer to the online Australian Immunisation Handbook
  • Booster doses are also available for people with these conditions with ongoing risk. Refer to the online Australian Immunisation Handbook for dosing requirements.

Haemophilus influenzae type b (Act-HIB)

All people aged 5 years and over with asplenia or hyposplenia that were incompletely vaccinated or not vaccinated during childhood are recommended and funded to receive one dose of Act-HIB.

Resources

​​​
Page Updated: Monday 29 June 2020
Contact page owner: Immunisation